Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice

Recent advances in immuno-oncology have shown that the immune system can be activated to induce long-term, durable antitumor responses. For immuno-oncology drug development, immune activation is often explored using rat Abs in immunocompetent mouse models. Although these models can be used to show e...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of immunology (1950) Vol. 198; no. 11; pp. 4502 - 4512
Main Authors Belmar, Nicole A, Chan, Sarah W, Fox, Melvin I, Samayoa, Josue A, Stickler, Marcia M, Tran, Ninian N, Akamatsu, Yoshiko, Hollenbaugh, Diane, Harding, Fiona A, Alvarez, Hamsell M
Format Journal Article
LanguageEnglish
Published United States American Association of Immunologists 01.06.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Recent advances in immuno-oncology have shown that the immune system can be activated to induce long-term, durable antitumor responses. For immuno-oncology drug development, immune activation is often explored using rat Abs in immunocompetent mouse models. Although these models can be used to show efficacy, antidrug immune responses to experimental protein-based therapeutics can arise. Immunogenicity of surrogate Abs may therefore represent an important obstacle to the evaluation of the antitumor efficacy of immunomodulator Abs in syngeneic models. A recent publication has shown that anti-glucocorticoid-induced TNFR family-related protein agonistic Ab DTA-1 (rat or murinized IgG2a) can induce the development of anaphylaxis in C57BL/6 mice upon repeated i.p. dosing because of an anti-idiotypic anti-drug Ab immune response. This study was undertaken to address the impact of the immunogenicity derived from the Fc and variable domains. To this end, chimerized (rat V domains/mouse constant regions) and murinized (95% mouse sequence) DTA-1-based surrogate Abs with a murine IgG2c H chain isotype were created. Chimerization and murinization of DTA-1 did not affect receptor binding and glucocorticoid-induced TNFR family-related protein-induced T cell agonistic properties. Similar in vivo antitumor efficacy and intratumoral CD8 /regulatory T cells were also observed. Finally, treatment of C57BL/6 mice with the chimerized and murinized DTA-1 Abs on a C57BL/6-matched IgG2c isotype resulted in reduced development and severity of anaphylaxis as measured by decline of body temperature, behavioral effects, serum IL-4, IgE, and anti-drug Ab levels. These results suggest that careful murinization and selection of a strain-matched H chain isotype are critical to generate ideal surrogate Abs for testing immuno-oncology mechanisms in vivo.
AbstractList Recent advances in immuno-oncology have shown that the immune system can be activated to induce long-term, durable antitumor responses. For immuno-oncology drug development, immune activation is often explored using rat Abs in immunocompetent mouse models. Although these models can be used to show efficacy, antidrug immune responses to experimental protein-based therapeutics can arise. Immunogenicity of surrogate Abs may therefore represent an important obstacle to the evaluation of the antitumor efficacy of immunomodulator Abs in syngeneic models. A recent publication has shown that anti-glucocorticoid–induced TNFR family–related protein agonistic Ab DTA-1 (rat or murinized IgG2a) can induce the development of anaphylaxis in C57BL/6 mice upon repeated i.p. dosing because of an anti-idiotypic anti-drug Ab immune response. This study was undertaken to address the impact of the immunogenicity derived from the Fc and variable domains. To this end, chimerized (rat V domains/mouse constant regions) and murinized (95% mouse sequence) DTA-1–based surrogate Abs with a murine IgG2c H chain isotype were created. Chimerization and murinization of DTA-1 did not affect receptor binding and glucocorticoid-induced TNFR family–related protein–induced T cell agonistic properties. Similar in vivo antitumor efficacy and intratumoral CD8+/regulatory T cells were also observed. Finally, treatment of C57BL/6 mice with the chimerized and murinized DTA-1 Abs on a C57BL/6-matched IgG2c isotype resulted in reduced development and severity of anaphylaxis as measured by decline of body temperature, behavioral effects, serum IL-4, IgE, and anti-drug Ab levels. These results suggest that careful murinization and selection of a strain-matched H chain isotype are critical to generate ideal surrogate Abs for testing immuno-oncology mechanisms in vivo.
Recent advances in immuno-oncology have shown that the immune system can be activated to induce long-term, durable antitumor responses. For immuno-oncology drug development, immune activation is often explored using rat Abs in immunocompetent mouse models. Although these models can be used to show efficacy, antidrug immune responses to experimental protein-based therapeutics can arise. Immunogenicity of surrogate Abs may therefore represent an important obstacle to the evaluation of the antitumor efficacy of immunomodulator Abs in syngeneic models. A recent publication has shown that anti-glucocorticoid-induced TNFR family-related protein agonistic Ab DTA-1 (rat or murinized IgG2a) can induce the development of anaphylaxis in C57BL/6 mice upon repeated i.p. dosing because of an anti-idiotypic anti-drug Ab immune response. This study was undertaken to address the impact of the immunogenicity derived from the Fc and variable domains. To this end, chimerized (rat V domains/mouse constant regions) and murinized (95% mouse sequence) DTA-1-based surrogate Abs with a murine IgG2c H chain isotype were created. Chimerization and murinization of DTA-1 did not affect receptor binding and glucocorticoid-induced TNFR family-related protein-induced T cell agonistic properties. Similar in vivo antitumor efficacy and intratumoral CD8 /regulatory T cells were also observed. Finally, treatment of C57BL/6 mice with the chimerized and murinized DTA-1 Abs on a C57BL/6-matched IgG2c isotype resulted in reduced development and severity of anaphylaxis as measured by decline of body temperature, behavioral effects, serum IL-4, IgE, and anti-drug Ab levels. These results suggest that careful murinization and selection of a strain-matched H chain isotype are critical to generate ideal surrogate Abs for testing immuno-oncology mechanisms in vivo.
Author Samayoa, Josue A
Fox, Melvin I
Tran, Ninian N
Harding, Fiona A
Hollenbaugh, Diane
Chan, Sarah W
Alvarez, Hamsell M
Stickler, Marcia M
Akamatsu, Yoshiko
Belmar, Nicole A
Author_xml – sequence: 1
  givenname: Nicole A
  surname: Belmar
  fullname: Belmar, Nicole A
  organization: Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063
– sequence: 2
  givenname: Sarah W
  surname: Chan
  fullname: Chan, Sarah W
  organization: Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063
– sequence: 3
  givenname: Melvin I
  surname: Fox
  fullname: Fox, Melvin I
  organization: Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063
– sequence: 4
  givenname: Josue A
  surname: Samayoa
  fullname: Samayoa, Josue A
  organization: Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063
– sequence: 5
  givenname: Marcia M
  surname: Stickler
  fullname: Stickler, Marcia M
  organization: Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063
– sequence: 6
  givenname: Ninian N
  surname: Tran
  fullname: Tran, Ninian N
  organization: Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063
– sequence: 7
  givenname: Yoshiko
  surname: Akamatsu
  fullname: Akamatsu, Yoshiko
  organization: Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063
– sequence: 8
  givenname: Diane
  surname: Hollenbaugh
  fullname: Hollenbaugh, Diane
  organization: Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063
– sequence: 9
  givenname: Fiona A
  orcidid: 0000-0003-3817-1203
  surname: Harding
  fullname: Harding, Fiona A
  organization: Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063
– sequence: 10
  givenname: Hamsell M
  surname: Alvarez
  fullname: Alvarez, Hamsell M
  email: hamsell.alvarezjares@abbvie.com
  organization: Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063 hamsell.alvarezjares@abbvie.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28446565$$D View this record in MEDLINE/PubMed
BookMark eNqFkT1v2zAQhokiReOk3TsVBLp0UXKk-KXRdZvEgI0CgTsLFEnFNCTSFSmg6t7_HTVxOnTpdDc874M7vBfoLMTgEHpP4IoBq64Pvu_HELsrIoBwQl-hBeEcCiFAnKEFAKUFkUKeo4uUDgAggLI36JwqxgQXfIF-b8fBB_9LZx8D1sHiO7zaax_wOsU8HR3e6mz2Pjzg2OK8d3gZsi9u17v7p62JdsJfdsuC4HtnR-MSXj_d9OCCNz5PxdZZr7OzM66P-6nTP33Cs3_F5efNtcBbb9xb9LrVXXLvTvMSfb_5ulvdFZtvt-vVclMYBjQXrLVgJAfVUCeJgpITpctKC81t28j5qbJtaGOJkbZteWWUYA3lLXeU0Mqp8hJ9evYeh_hjdCnXvU_GdZ0OLo6pJhUIJkip5P9RVVFJqazIjH78Bz3EcQjzI7NQsVJSKWCm4JkyQ0xpcG19HHyvh6kmUP9ps35psz61OUc-nMRj0zv7N_BSX_kIfECcbQ
CitedBy_id crossref_primary_10_1016_j_ymthe_2020_02_007
crossref_primary_10_1038_s43018_022_00334_9
crossref_primary_10_1186_s40425_019_0671_4
Cites_doi 10.4161/mabs.2.3.11782
10.1097/00007890-199004000-00009
10.1007/BF00395856
10.1038/nbt1303
10.1182/blood-2013-12-544742
10.1084/jem.20130573
10.1158/1078-0432.CCR-12-2982
10.1038/icb.2014.26
10.1124/jpet.115.229864
10.1097/CJI.0b013e3181ee6ba9
10.4049/jimmunol.1300409
10.1038/nrc3239
10.1200/JCO.2001.19.13.3280
10.1080/2162402X.2015.1075114
10.1038/nri3405
10.1158/1078-0432.CCR-09-3243
10.1084/jem.20130590
10.3389/fimmu.2016.00021
10.1016/S0022-1759(98)00015-5
10.4049/jimmunol.174.12.7869
10.1056/NEJMoa1302369
10.1016/j.coi.2013.12.005
10.1186/1479-5876-12-36
10.1158/1538-7445.AM2015-4521
10.1371/journal.pone.0010436
10.1056/NEJMoa1003466
10.4049/jimmunol.176.11.6434
10.1124/jpet.113.207605
10.1038/nrd3930
10.1038/nri1371
10.1016/j.molimm.2011.11.006
10.1158/1535-7163.MCT-08-0993
10.1002/eji.200324804
10.1126/science.aaa8172
10.1155/2010/239083
10.1016/j.ymeth.2005.01.001
10.1056/NEJMoa1305133
10.1126/science.1198443
10.1016/j.coi.2013.01.004
10.1093/protein/gzs044
10.1056/NEJMoa063842
10.1158/1078-0432.CCR-12-2214
10.1038/nature10673
10.4049/jimmunol.179.11.7365
10.1093/ecco-jcc/jjv179
10.1073/pnas.78.7.4495
10.1056/NEJMoa1104621
10.1084/jem.20050940
10.4161/mabs.2.3.11641
10.1038/ni759
10.1172/JCI73014
10.1002/j.1460-2075.1989.tb08484.x
10.1158/2326-6066.CIR-13-0031-T
10.4161/mabs.3.5.16326
10.1073/pnas.94.12.6216
10.1016/j.addr.2006.01.026
10.1182/blood-2001-12-0276
10.1084/jem.20130579
10.1056/NEJMoa1200690
10.1158/1078-0432.CCR-07-0940
10.1016/S1359-6446(03)02953-2
ContentType Journal Article
Copyright Copyright © 2017 by The American Association of Immunologists, Inc.
Copyright American Association of Immunologists Jun 1, 2017
Copyright_xml – notice: Copyright © 2017 by The American Association of Immunologists, Inc.
– notice: Copyright American Association of Immunologists Jun 1, 2017
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7QR
7T5
7TK
7TM
7U9
8FD
FR3
H94
M7N
P64
RC3
7X8
DOI 10.4049/jimmunol.1601512
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Immunology Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Genetics Abstracts
Virology and AIDS Abstracts
Technology Research Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Immunology Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList Genetics Abstracts
CrossRef
MEDLINE - Academic
MEDLINE
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1550-6606
EndPage 4512
ExternalDocumentID 10_4049_jimmunol_1601512
28446565
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
18M
2WC
34G
39C
53G
5GY
5RE
5VS
79B
85S
AARDX
ABCQX
ABJNI
ABOCM
ABPPZ
ACGFO
ACGFS
ACIWK
ACNCT
ACPRK
ADBBV
ADNWM
AENEX
AFHIN
AFOSN
AFRAH
AHWXS
AIZAD
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CGR
CUY
CVF
D0L
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
FRP
GX1
IH2
K-O
KQ8
L7B
NPM
OK1
P0W
P2P
PQQKQ
R.V
RHF
RHI
RZQ
SJN
TR2
TWZ
W8F
WH7
WOQ
X7M
XSW
XTH
YHG
5WD
AAYXX
ABEJV
CITATION
OCZFY
7QP
7QR
7T5
7TK
7TM
7U9
8FD
FR3
H94
M7N
P64
RC3
7X8
ID FETCH-LOGICAL-c402t-4fd0c7508b2e71803518a39a6a5dfb78443fb2bd1c7dff59c864b25f5e2129e83
ISSN 0022-1767
IngestDate Wed Dec 04 03:51:28 EST 2024
Wed Dec 04 02:31:00 EST 2024
Thu Oct 10 22:02:53 EDT 2024
Fri Dec 06 01:27:22 EST 2024
Sat Sep 28 08:49:05 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
License Copyright © 2017 by The American Association of Immunologists, Inc.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c402t-4fd0c7508b2e71803518a39a6a5dfb78443fb2bd1c7dff59c864b25f5e2129e83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-3817-1203
OpenAccessLink https://www.jimmunol.org/content/jimmunol/198/11/4502.full.pdf
PMID 28446565
PQID 1984372760
PQPubID 105689
PageCount 11
ParticipantIDs proquest_miscellaneous_1906461387
proquest_miscellaneous_1892722791
proquest_journals_1984372760
crossref_primary_10_4049_jimmunol_1601512
pubmed_primary_28446565
PublicationCentury 2000
PublicationDate 2017-06-01
20170601
PublicationDateYYYYMMDD 2017-06-01
PublicationDate_xml – month: 06
  year: 2017
  text: 2017-06-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Baltimore
PublicationTitle The Journal of immunology (1950)
PublicationTitleAlternate J Immunol
PublicationYear 2017
Publisher American Association of Immunologists
Publisher_xml – name: American Association of Immunologists
References Mall (2023010209334425600_r55) 2015; 5
Ascierto (2023010209334425600_r53) 2013; 19
Kohrt (2023010209334425600_r17) 2014; 124
Bulliard (2023010209334425600_r31) 2013; 210
2023010209334425600_r63
2023010209334425600_r62
Robert (2023010209334425600_r7) 2011; 364
Fan (2023010209334425600_r18) 2014; 211
Schreier (2023010209334425600_r45) 1981; 78
Hwang (2023010209334425600_r60) 2005; 36
McRae (2023010209334425600_r49) 2016; 10
Pardoll (2023010209334425600_r5) 2012; 12
Cohen (2023010209334425600_r30) 2010; 5
Digiammarino (2023010209334425600_r48) 2011; 3
Esparza (2023010209334425600_r26) 2005; 174
Brunn (2023010209334425600_r54) 2016; 356
Topalian (2023010209334425600_r3) 2012; 366
Brennan (2023010209334425600_r40) 2010; 2
Ovacik (2023010209334425600_r50) 2015; 75
Nocentini (2023010209334425600_r22) 1997; 94
Hamid (2023010209334425600_r4) 2013; 369
Hu (2023010209334425600_r29) 2008; 14
Murphy (2023010209334425600_r42) 2014; 123
Croft (2023010209334425600_r9) 2013; 12
Sugamura (2023010209334425600_r14) 2004; 4
Beatty (2023010209334425600_r13) 2011; 331
Mitsui (2023010209334425600_r36) 2010; 16
Lu (2023010209334425600_r37) 2014; 12
Kim (2023010209334425600_r16) 2009; 8
Lacal (2023010209334425600_r28) 2013; 347
Zhang (2023010209334425600_r47) 2012; 50
Shankar (2023010209334425600_r56) 2007; 25
Vonderheide (2023010209334425600_r12) 2001; 19
Chen (2023010209334425600_r11) 2013; 13
Ko (2023010209334425600_r35) 2005; 202
Ronchetti (2023010209334425600_r27) 2004; 34
Krishna (2023010209334425600_r57) 2016; 7
Nishikawa (2023010209334425600_r21) 2014; 27
Bulliard (2023010209334425600_r51) 2014; 92
Melero (2023010209334425600_r10) 2013; 19
Martin (2023010209334425600_r46) 1998; 212
Zhou (2023010209334425600_r33) 2010; 33
Suntharalingam (2023010209334425600_r39) 2006; 355
Sharma (2023010209334425600_r2) 2015; 348
Jouvin-Marche (2023010209334425600_r43) 1989; 29
Hodi (2023010209334425600_r6) 2010; 363
Ronchetti (2023010209334425600_r24) 2002; 100
Ramirez-Montagut (2023010209334425600_r34) 2006; 176
Chatenoud (2023010209334425600_r38) 1990; 49
Morgado (2023010209334425600_r44) 1989; 8
Moran (2023010209334425600_r20) 2013; 25
He (2023010209334425600_r19) 2013; 191
Shimizu (2023010209334425600_r25) 2002; 3
Zhou (2023010209334425600_r32) 2007; 179
Placke (2023010209334425600_r23) 2010; 2010
Harding (2023010209334425600_r58) 2010; 2
Wolchok (2023010209334425600_r8) 2013; 369
Chirino (2023010209334425600_r41) 2004; 9
Presta (2023010209334425600_r61) 2006; 58
Redmond (2023010209334425600_r15) 2014; 2
Osipovitch (2023010209334425600_r59) 2012; 25
Simpson (2023010209334425600_r52) 2013; 210
Mellman (2023010209334425600_r1) 2011; 480
References_xml – volume: 2
  start-page: 233
  year: 2010
  ident: 2023010209334425600_r40
  article-title: Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.
  publication-title: MAbs
  doi: 10.4161/mabs.2.3.11782
  contributor:
    fullname: Brennan
– volume: 49
  start-page: 697
  year: 1990
  ident: 2023010209334425600_r38
  article-title: In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids.
  publication-title: Transplantation
  doi: 10.1097/00007890-199004000-00009
  contributor:
    fullname: Chatenoud
– volume: 29
  start-page: 92
  year: 1989
  ident: 2023010209334425600_r43
  article-title: The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes.
  publication-title: Immunogenetics
  doi: 10.1007/BF00395856
  contributor:
    fullname: Jouvin-Marche
– volume: 25
  start-page: 555
  year: 2007
  ident: 2023010209334425600_r56
  article-title: A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs.
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt1303
  contributor:
    fullname: Shankar
– volume: 123
  start-page: 2172
  year: 2014
  ident: 2023010209334425600_r42
  article-title: Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.
  publication-title: Blood
  doi: 10.1182/blood-2013-12-544742
  contributor:
    fullname: Murphy
– volume: 210
  start-page: 1685
  year: 2013
  ident: 2023010209334425600_r31
  article-title: Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20130573
  contributor:
    fullname: Bulliard
– ident: 2023010209334425600_r63
– volume: 19
  start-page: 1009
  year: 2013
  ident: 2023010209334425600_r53
  article-title: Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-2982
  contributor:
    fullname: Ascierto
– volume: 92
  start-page: 475
  year: 2014
  ident: 2023010209334425600_r51
  article-title: OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
  publication-title: Immunol. Cell Biol.
  doi: 10.1038/icb.2014.26
  contributor:
    fullname: Bulliard
– volume: 356
  start-page: 574
  year: 2016
  ident: 2023010209334425600_r54
  article-title: The role of anti-drug antibodies in the pharmacokinetics, disposition, target engagement, and efficacy of a GITR agonist monoclonal antibody in mice.
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.115.229864
  contributor:
    fullname: Brunn
– volume: 33
  start-page: 789
  year: 2010
  ident: 2023010209334425600_r33
  article-title: Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e3181ee6ba9
  contributor:
    fullname: Zhou
– volume: 191
  start-page: 4174
  year: 2013
  ident: 2023010209334425600_r19
  article-title: Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1300409
  contributor:
    fullname: He
– volume: 12
  start-page: 252
  year: 2012
  ident: 2023010209334425600_r5
  article-title: The blockade of immune checkpoints in cancer immunotherapy.
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3239
  contributor:
    fullname: Pardoll
– volume: 19
  start-page: 3280
  year: 2001
  ident: 2023010209334425600_r12
  article-title: Phase I study of recombinant human CD40 ligand in cancer patients.
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2001.19.13.3280
  contributor:
    fullname: Vonderheide
– volume: 5
  start-page: e1075114
  year: 2015
  ident: 2023010209334425600_r55
  article-title: Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2015.1075114
  contributor:
    fullname: Mall
– volume: 13
  start-page: 227
  year: 2013
  ident: 2023010209334425600_r11
  article-title: Molecular mechanisms of T cell co-stimulation and co-inhibition.
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3405
  contributor:
    fullname: Chen
– volume: 16
  start-page: 2781
  year: 2010
  ident: 2023010209334425600_r36
  article-title: Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-09-3243
  contributor:
    fullname: Mitsui
– volume: 211
  start-page: 715
  year: 2014
  ident: 2023010209334425600_r18
  article-title: Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20130590
  contributor:
    fullname: Fan
– volume: 7
  start-page: 21
  year: 2016
  ident: 2023010209334425600_r57
  article-title: Immunogenicity to Biotherapeutics – the role of anti-drug immune complexes.
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2016.00021
  contributor:
    fullname: Krishna
– volume: 212
  start-page: 187
  year: 1998
  ident: 2023010209334425600_r46
  article-title: The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice.
  publication-title: J. Immunol. Methods
  doi: 10.1016/S0022-1759(98)00015-5
  contributor:
    fullname: Martin
– volume: 174
  start-page: 7869
  year: 2005
  ident: 2023010209334425600_r26
  article-title: Glucocorticoid-induced TNF receptor functions as a costimulatory receptor that promotes survival in early phases of T cell activation.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.174.12.7869
  contributor:
    fullname: Esparza
– volume: 369
  start-page: 122
  year: 2013
  ident: 2023010209334425600_r8
  article-title: Nivolumab plus ipilimumab in advanced melanoma.
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1302369
  contributor:
    fullname: Wolchok
– volume: 27
  start-page: 1
  year: 2014
  ident: 2023010209334425600_r21
  article-title: Regulatory T cells in cancer immunotherapy.
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2013.12.005
  contributor:
    fullname: Nishikawa
– volume: 12
  start-page: 36
  year: 2014
  ident: 2023010209334425600_r37
  article-title: Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
  publication-title: J. Transl. Med.
  doi: 10.1186/1479-5876-12-36
  contributor:
    fullname: Lu
– volume: 75
  start-page: 4521
  year: 2015
  ident: 2023010209334425600_r50
  article-title: Evaluation of the relationship between serum exposure, receptor (GITR) availability and tumor suppression following administration of the anti-GITR antibody DX400 in mouse syngeneic tumor models
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.AM2015-4521
  contributor:
    fullname: Ovacik
– volume: 5
  start-page: e10436
  year: 2010
  ident: 2023010209334425600_r30
  article-title: Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0010436
  contributor:
    fullname: Cohen
– volume: 363
  start-page: 711
  year: 2010
  ident: 2023010209334425600_r6
  article-title: Improved survival with ipilimumab in patients with metastatic melanoma.
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1003466
  contributor:
    fullname: Hodi
– volume: 176
  start-page: 6434
  year: 2006
  ident: 2023010209334425600_r34
  article-title: Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.176.11.6434
  contributor:
    fullname: Ramirez-Montagut
– volume: 347
  start-page: 164
  year: 2013
  ident: 2023010209334425600_r28
  article-title: Glucocorticoid-induced tumor necrosis factor receptor family-related ligand triggering upregulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 and promotes leukocyte adhesion.
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.113.207605
  contributor:
    fullname: Lacal
– volume: 12
  start-page: 147
  year: 2013
  ident: 2023010209334425600_r9
  article-title: Clinical targeting of the TNF and TNFR superfamilies.
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd3930
  contributor:
    fullname: Croft
– volume: 4
  start-page: 420
  year: 2004
  ident: 2023010209334425600_r14
  article-title: Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri1371
  contributor:
    fullname: Sugamura
– volume: 50
  start-page: 169
  year: 2012
  ident: 2023010209334425600_r47
  article-title: Possible allelic structure of IgG2a and IgG2c in mice.
  publication-title: Mol. Immunol.
  doi: 10.1016/j.molimm.2011.11.006
  contributor:
    fullname: Zhang
– volume: 8
  start-page: 469
  year: 2009
  ident: 2023010209334425600_r16
  article-title: Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy.
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-08-0993
  contributor:
    fullname: Kim
– volume: 34
  start-page: 613
  year: 2004
  ident: 2023010209334425600_r27
  article-title: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations.
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.200324804
  contributor:
    fullname: Ronchetti
– volume: 348
  start-page: 56
  year: 2015
  ident: 2023010209334425600_r2
  article-title: The future of immune checkpoint therapy.
  publication-title: Science
  doi: 10.1126/science.aaa8172
  contributor:
    fullname: Sharma
– volume: 2010
  start-page: 239083
  year: 2010
  ident: 2023010209334425600_r23
  article-title: Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation.
  publication-title: Clin. Dev. Immunol.
  doi: 10.1155/2010/239083
  contributor:
    fullname: Placke
– volume: 36
  start-page: 3
  year: 2005
  ident: 2023010209334425600_r60
  article-title: Immunogenicity of engineered antibodies.
  publication-title: Methods
  doi: 10.1016/j.ymeth.2005.01.001
  contributor:
    fullname: Hwang
– volume: 369
  start-page: 134
  year: 2013
  ident: 2023010209334425600_r4
  article-title: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1305133
  contributor:
    fullname: Hamid
– volume: 331
  start-page: 1612
  year: 2011
  ident: 2023010209334425600_r13
  article-title: CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
  publication-title: Science
  doi: 10.1126/science.1198443
  contributor:
    fullname: Beatty
– volume: 25
  start-page: 230
  year: 2013
  ident: 2023010209334425600_r20
  article-title: The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2013.01.004
  contributor:
    fullname: Moran
– volume: 25
  start-page: 613
  year: 2012
  ident: 2023010209334425600_r59
  article-title: Design and analysis of immune-evading enzymes for ADEPT therapy.
  publication-title: Protein Eng. Des. Sel.
  doi: 10.1093/protein/gzs044
  contributor:
    fullname: Osipovitch
– volume: 355
  start-page: 1018
  year: 2006
  ident: 2023010209334425600_r39
  article-title: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa063842
  contributor:
    fullname: Suntharalingam
– volume: 19
  start-page: 997
  year: 2013
  ident: 2023010209334425600_r10
  article-title: Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-2214
  contributor:
    fullname: Melero
– volume: 480
  start-page: 480
  year: 2011
  ident: 2023010209334425600_r1
  article-title: Cancer immunotherapy comes of age.
  publication-title: Nature
  doi: 10.1038/nature10673
  contributor:
    fullname: Mellman
– volume: 179
  start-page: 7365
  year: 2007
  ident: 2023010209334425600_r32
  article-title: Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.179.11.7365
  contributor:
    fullname: Zhou
– volume: 10
  start-page: 69
  year: 2016
  ident: 2023010209334425600_r49
  article-title: Fc receptor-mediated effector function contributes to the therapeutic response of anti-TNF monoclonal antibodies in a mouse model of inflammatory bowel disease.
  publication-title: J. Crohns Colitis
  doi: 10.1093/ecco-jcc/jjv179
  contributor:
    fullname: McRae
– volume: 78
  start-page: 4495
  year: 1981
  ident: 2023010209334425600_r45
  article-title: Multiple differences between the nucleic acid sequences of the IgG2aa and IgG2ab alleles of the mouse.
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.78.7.4495
  contributor:
    fullname: Schreier
– volume: 364
  start-page: 2517
  year: 2011
  ident: 2023010209334425600_r7
  article-title: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1104621
  contributor:
    fullname: Robert
– volume: 202
  start-page: 885
  year: 2005
  ident: 2023010209334425600_r35
  article-title: Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20050940
  contributor:
    fullname: Ko
– ident: 2023010209334425600_r62
– volume: 2
  start-page: 256
  year: 2010
  ident: 2023010209334425600_r58
  article-title: The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.
  publication-title: MAbs
  doi: 10.4161/mabs.2.3.11641
  contributor:
    fullname: Harding
– volume: 3
  start-page: 135
  year: 2002
  ident: 2023010209334425600_r25
  article-title: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.
  publication-title: Nat. Immunol.
  doi: 10.1038/ni759
  contributor:
    fullname: Shimizu
– volume: 124
  start-page: 2668
  year: 2014
  ident: 2023010209334425600_r17
  article-title: Targeting CD137 enhances the efficacy of cetuximab.
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI73014
  contributor:
    fullname: Kohrt
– volume: 8
  start-page: 3245
  year: 1989
  ident: 2023010209334425600_r44
  article-title: Further evidence that BALB/c and C57BL/6 γ 2a genes originate from two distinct isotypes.
  publication-title: EMBO J.
  doi: 10.1002/j.1460-2075.1989.tb08484.x
  contributor:
    fullname: Morgado
– volume: 2
  start-page: 142
  year: 2014
  ident: 2023010209334425600_r15
  article-title: Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-13-0031-T
  contributor:
    fullname: Redmond
– volume: 3
  start-page: 487
  year: 2011
  ident: 2023010209334425600_r48
  article-title: Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design.
  publication-title: MAbs
  doi: 10.4161/mabs.3.5.16326
  contributor:
    fullname: Digiammarino
– volume: 94
  start-page: 6216
  year: 1997
  ident: 2023010209334425600_r22
  article-title: A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis.
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.94.12.6216
  contributor:
    fullname: Nocentini
– volume: 58
  start-page: 640
  year: 2006
  ident: 2023010209334425600_r61
  article-title: Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2006.01.026
  contributor:
    fullname: Presta
– volume: 100
  start-page: 350
  year: 2002
  ident: 2023010209334425600_r24
  article-title: Role of GITR in activation response of T lymphocytes.
  publication-title: Blood
  doi: 10.1182/blood-2001-12-0276
  contributor:
    fullname: Ronchetti
– volume: 210
  start-page: 1695
  year: 2013
  ident: 2023010209334425600_r52
  article-title: Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20130579
  contributor:
    fullname: Simpson
– volume: 366
  start-page: 2443
  year: 2012
  ident: 2023010209334425600_r3
  article-title: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1200690
  contributor:
    fullname: Topalian
– volume: 14
  start-page: 579
  year: 2008
  ident: 2023010209334425600_r29
  article-title: Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer.
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-0940
  contributor:
    fullname: Hu
– volume: 9
  start-page: 82
  year: 2004
  ident: 2023010209334425600_r41
  article-title: Minimizing the immunogenicity of protein therapeutics.
  publication-title: Drug Discov. Today
  doi: 10.1016/S1359-6446(03)02953-2
  contributor:
    fullname: Chirino
SSID ssj0006024
Score 2.294251
Snippet Recent advances in immuno-oncology have shown that the immune system can be activated to induce long-term, durable antitumor responses. For immuno-oncology...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
StartPage 4502
SubjectTerms Anaphylaxis
Anaphylaxis - immunology
Animal models
Animals
Antitumor activity
Body temperature
Cancer immunotherapy
CD8 antigen
CD8-Positive T-Lymphocytes - immunology
Cell Line, Tumor
Drug development
Glucocorticoid-Induced TNFR-Related Protein - immunology
Glucocorticoids
Immune response
Immunogenicity
Immunoglobulin E
Immunoglobulin G
Immunoglobulin Isotypes - immunology
Immunoregulation
Interleukin 4
Interleukin-4 - immunology
Lymphocytes
Lymphocytes T
Mice
Mice, Inbred C57BL
Oncology
Proteins
Rats
Receptors, IgG - immunology
Strain
T-Lymphocytes, Regulatory - immunology
Tumor necrosis factor receptors
Title Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice
URI https://www.ncbi.nlm.nih.gov/pubmed/28446565
https://www.proquest.com/docview/1984372760
https://search.proquest.com/docview/1892722791
https://search.proquest.com/docview/1906461387
Volume 198
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLbKEIgLggGjMJCR4ICqdI5jx8mx24AWKAfoxG5R7DiiUkkQaxDlzr_H38Sz46RpRRHjEkVu9Or4fXn-7PfDCD2lMKmmXHOPSUU9RlPiSaIjL5KhJCmJVVBH-b4Lx2fs9Tk_7_V-daKWqqUcqh9_zCv5H61CG-jVZMleQrOtUGiAe9AvXEHDcP0nHU-t_6VOpLRegLFxn8-LweSitHurUzC0n1xcs80hKZZz79Vk9t7eyTJbDU5nI8-HUc4qE5s1MekiJfzhXAE996b2IA_gpKPC1LVepN_nNn72hIvjt9Dv0ITdbwQTrVPN6moUVp4t8_TMOtNIZ-vhWC9cfLfFI3Rv2Ik2KNoN68HHtt1NllO9-GZes23_kH5OV2XqfBpVK8rtZ_hiHXfVyS_wRX1Ix1A7s8xhkRuScMNux1EXoH7HDDNOaGdKZ7wO1d6eLhgsj8x04cbC7LT57tHNytxbM2YbxwgrKCMjaSQkTsIVdNUUZjRnOZxO3rTMICSUNdXrzRvWbnMj4Wi7D5s0acfax3Kg2S100-kVj2ok3kY9Xeyja_Vxpqt9dH3qAjXuoJ9daGKAJh5jC03soIkbaOIyxwBN3EITN9DEFprYQRPvgCbuQBODfAvNoxAbYN5FZy9fzE7Gnjvxw1OM0KXH8owo4LCRpBpIk_FyR2kQp2BOslyKiLEgl1RmvhJZnvNYRSGTlOdcAwOLdRTcQ3tFWej7CCtfSyV8HTMZMOoroN2x4IJSFUjDovvoeTPAyZe6sEuyS519dNhoIHGf_0UC8DM-bxGSPnrS_gzG2Xjc0kKXFTwTxVSYGp3-X56JYVUApDoSfXRQa7ftEHBHU8-QP7hEZx-iG-vP6hDtLb9W-hEQ56V8bNH4GxfNvvk
link.rule.ids 314,780,784,27924,27925
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Murinization+and+H+Chain+Isotype+Matching+of+the+Anti-GITR+Antibody+DTA-1+Reduces+Immunogenicity-Mediated+Anaphylaxis+in+C57BL%2F6+Mice&rft.jtitle=The+Journal+of+immunology+%281950%29&rft.au=Belmar%2C+Nicole+A.&rft.au=Chan%2C+Sarah+W.&rft.au=Fox%2C+Melvin+I.&rft.au=Samayoa%2C+Josue+A.&rft.date=2017-06-01&rft.issn=0022-1767&rft.eissn=1550-6606&rft.volume=198&rft.issue=11&rft.spage=4502&rft.epage=4512&rft_id=info:doi/10.4049%2Fjimmunol.1601512&rft.externalDBID=n%2Fa&rft.externalDocID=10_4049_jimmunol_1601512
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1767&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1767&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1767&client=summon